PARP Inhibitors Market is expected to reach US$ 6.64 billion by 2031 | Top Companies - AstraZeneca, Pfizer Inc., GSK plc, Pharmaand GmbH.

Market Size and Growth:

The Global PARP Inhibitors Market size reached US$ 3.53 billion in 2023 and is expected to reach US$ 6.64 billion by 2031, growing at a CAGR of 8.3% during the forecast period 2024-2031.

The PARP Inhibitors Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/parp-inhibitors-market?sz

The PARP Inhibitors Market encompasses the global development, manufacturing, and commercialization of drugs that block poly (ADP-ribose) polymerase enzymes, used primarily in cancer therapy to prevent DNA repair in tumor cells. It covers indications, drug classes, distribution channels, key players, and clinical applications across ovarian, breast, prostate, and other solid tumors worldwide.

Recent Key Developments of United States:

✅ December 2025: Multiple PARP inhibitors received expanded confirmations for HR-mutated cancers, including rucaparib's traditional approval for BRCA-mutated mCRPC post-androgen therapy, solidifying their efficacy in oncology pipelines.

✅ November 2025: Ongoing advancements in ovarian cancer treatments highlighted PARP inhibitors' role alongside new trials like ROSELLA and KEYNOTE-B96, emphasizing their integration in precision medicine for recurrent cases.

✅ October 2025: The FDA approved niraparib combined with abiraterone acetate (Akeega) and prednisone for HR-mutated metastatic castration-sensitive prostate cancer with BRCA2 mutations, marking the first PARP inhibitor approval for this setting before castration resistance develops.

Recent Key Developments of Japan:

✅ December 2025: Expanded national health insurance listing for PARP inhibitors in HRD-positive tumors increased patient affordability and usage in Japan's aging population.

✅ November 2025: Domestic trials by a Japanese pharma leader showed promising efficacy of PARP inhibitors combined with targeted therapies for gastric cancer, a key local indication.

✅ October 2025: Japan's PMDA granted conditional approval for an imported PARP inhibitor for maintenance therapy in platinum-sensitive ovarian cancer, accelerating adoption in precision medicine.

List of the Key Players in the PARP Inhibitors Market:

AstraZeneca
Pfizer Inc.
GSK plc
Pharmaand GmbH.
Globela Pharma
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Beacon Pharmaceuticals PLC
EVEREST

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/parp-inhibitors-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the PARP Inhibitors Market:

By Product Type: Olaparib, Niraparib, Rucaparib, Talazoparib, Others.

By Application: Breast Cancer, Ovarian Cancer, Prostate Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Others.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=parp-inhibitors-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, PARP Inhibitors market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global PARP Inhibitors Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global PARP Inhibitors market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the PARP Inhibitors Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the PARP Inhibitors Market in 2025?
◆ What is the projected growth rate of the PARP Inhibitors Market through 2033?
◆ Who are the key players in the PARP Inhibitors Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.